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The human antibody response engages in a lifelong thrust-and-parry interchange with influenza viruses that is sometimes a battle of equals, but other times turns fatal. One can appreciate a rough symmetry in the structures and sizes of antibody molecules and the surface proteins of influenza viruses, and both organisms use genetic hypervariability to manage the ongoing interaction with the other. Influenza viruses possess an error-prone RNA-dependent RNA polymerase complex. Human B cells in germinal centers, on the other hand, use activation-induced cytidine deaminase and error-protein DNA polymerases to accomplish double-stranded DNA breaks followed by repair with incorporation of missense mutations, insertions, and deletions. In large populations of susceptible hosts, influenza virus genes encoding surface proteins exhibit a gradual but steady "drift" of the sequences to encode viruses that exhibit decreased susceptibility to inhibition by the existing immunity in the herd of animals or population of humans at risk. It is intuitively obvious that altering the shape and chemical properties of an immunogen might lead to resistance to a single antibody with optimized fine specificity, but the molecular basis for the ability of a virus to escape the polyclonal response of antibodies in a large and diverse population is more subtle. Experts have puzzled for decades over this question. Recent improvements in human antibody technologies now allow us to capture virus-specific neutralizing human monoclonal antibodies with greater ease. Such studies are beginning to give us snapshots into the molecular mechanisms by which human antibodies neutralize influenza virus, and consequently, also allow us to define the mechanisms by which influenza virus escapes neutralization.

Classically, it was thought that antibody-resistant mutants acquired point mutations that abrogated binding by antibodies through alteration or elimination of a contact residue at the antigen-antibody interface. Alternatively, residues outside the actual interface that altered the scaffold supporting the interacting residues might become mutated, thus indirectly altering the shape complementarity at the interface. With older, less-sensitive techniques for measuring binding, it was thought that escape mutations in the viral protein nearly always eliminated binding of the antibody. More recently, it has become apparent that reduction of binding affinity below a certain threshold is sometimes adequate to mediate escape from inhibition, without complete loss of binding.

Antibody variable regions inhibit influenza virus using a large number of mechanisms that we are only beginning to understand. Essentially, if one studies the life cycle of influenza virus in cells, one can predict the ways in which antibodies might inhibit influenza virus. Mechanisms include blocking attachment to the sialic acid receptors on host cells, prevention of pH-mediated conformational changes in hemagglutinin (HA), prevention of virus-cell fusion, and even blocking of postfusion events in the virus replication program. The Fc portion of antibodies allows additional mechanisms to come into play; these mechanisms include complement fixation, uptake of antibody-virus complexes into cells via Fc or complement receptors, intracellular transport of IgM and IgA, and others. Emerging studies are pointing the way to an understanding that particular antibodies likely can interrupt most stages of the virus life cycle. In addition, in a symmetrical fashion, studies of mutant viruses, such as the one in the recent paper by O'Donnell et al. ([@B1]), reveal that influenza virus might accomplish escape from antibody neutralization by enhancing the efficiency of any step in its life cycle.

Interestingly, this paper reveals that the mechanism of escape from neutralization does not appear to be inextricably linked directly to the mechanism of neutralization. The investigators isolated a neutralizing human monoclonal antibody that recognizes the HA head domain, including an antigenic region typically designated the Sa site. Most of the antibody-resistant mutants selected *in vitro* by treatment with this antibody resulted in typical mutations that reduced binding of the antibody at the contact site. One mutant, however, achieved resistance to the neutralizing effect of the antibody principally by increasing its affinity for binding to a sialic acid receptor, which facilitated increased replication and pathogenicity in experimentally infected mice. These findings suggest that the end game in modulating pathogenesis is, for the most part, a very fine balance of quantitative factors. It is possible that any feature of the virus genome that enhances replication likely could contribute to "escape" or relative resistance to neutralization. If the full implications of this model are considered, it is obvious that even the internal proteins of influenza viruses that participate in replication and assembly might enhance replication of a virus strain even in the presence of a level of inhibitory antibodies that was able to contain a lower quantity or concentration of virus. The same could be considered for nonstructural proteins that interfere with the host innate immune response that limits viral replication.

This perspective begins to give us insight as to how an influenza virus may be able to sustain and diversify itself using a minimal number of changes in surface proteins in populations of immune individuals with a large number of antibody specificities to those very domains. In other words, we are gaining insight into the complexities of influenza virus antigenic drift. There are also broader implications for this work beyond the concept of drift. The receptor-binding residues on HA have the capability of mutating to alter affinity for differing linkages of sialic acid receptors, thus allowing an avian influenza virus to jump into mammalian hosts. It will be of interest to determine whether or not mammalian or avian antibody responses ever drive the change in host in nature. Furthermore, recent studies revealed the sparse number of amino acid changes needed to facilitate transmission of avian H5 viruses between mammalian hosts ([@B2], [@B3]).

Now that we understand better the dynamic relationship between escape mutations and receptor affinity, we should develop research capabilities to monitor the correspondence of the HA sequences of viruses that we isolate as antibody-resistant mutants and the viruses we observe occurring naturally in the field following infection or vaccination.
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